Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB

Oncogene

Volumn 23, Issue 40, 2004, Pages 6743-6759

  Schmelz, Karin ^a   Wieder, Thomas ^a   Tamm, Ingo ^a   Müller, Antje ^a   Essmann, Frank ^a   Geilen, Christoph C ^a   Schulze Osthoff, Klaus ^b   Dörken, Bernd ^a   Daniel, Peter T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Caspase 8; Drug resistance; Mitochondria; NF B; Tumor necrosis factor (TNF )

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CERAMIDE; CERAMIDE C2; CYTOCHROME C; EPIRUBICIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ANALYSIS; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MYELOID LEUKEMIA; PRIORITY JOURNAL; REED STERNBERG CELL; REGULATORY MECHANISM; SENSITIZATION; SIGNAL TRANSDUCTION;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, NORTHERN; CASPASE 8; CASPASES; CELL DEATH; CELL LINE, TUMOR; CERAMIDES; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; INTRACELLULAR MEMBRANES; LEUKEMIA, MYELOID; MEMBRANE POTENTIALS; MITOCHONDRIA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SPHINGOMYELINS; TUMOR NECROSIS FACTOR-ALPHA;

PHRAGMITES;

EID: 4644280684     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207848     Document Type: Article

References (94)

1. Baker SJ and Reddy EP. (1998). Oncogene, 17, 3261-3270.
2. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörken B. (1997). J. Clin. Invest., 12, 2961-2969.
3. Bargou RC, Mapara MY, Zugck C, Daniel PT, Pawlita M, Dohner H and Dörken B. (1993). J. Exp. Med., 177, 1257-1268.
4. Beg AA and Baltimore D. (1996). Science, 274, 782-784.
5. Belka C, Heinrich V, Marini P, Faltin H, Schulze-Osthoff K, Bamberg M and Budach W. (1999). Int. J. Radiat. Biol., 75, 1257-1264.
6. Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, Faltin H, Bamberg M, Budach W and Schulze-Osthoff K. (2000). Oncogene, 19, 1181-1190.
7. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K and Budach W. (2001). Oncogene, 20, 2190-2196.
8. Beyaert R, Heyninck K and Van Huffel S. (2000). Biochem. Pharmacol., 60, 1143-1151.
9. Beyaert R, Vanhaesebroeck B, Heyninck K, Boone E, De Valck D, Schulze-Osthoff K, Haegeman G, Van Roy F and Fiers W. (1993). Cancer Res., 53, 2623-2630.
10. Blagosklonny MV. (2000). Leukemia, 14, 1502-1508.
11. Bligh EG and Dyer WJ. (1959). Can. J. Biochem. Physiol., 37, 911-917.
12. Boldin MP, Goncharov TM, Goltsev YV and Wallach D. (1996). Cell, 85, 803-815.
13. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH and Wallach D. (1995). J. Biol. Chem., 270, 7795-7798.
14. Busuttil V, Bottero V, Frelin C, Imbert V, Ricci JE, Auberger P and Peyron JF. (2002). Oncogene, 21, 3213-3224.
15. Carpentier I and Beyaert R. (1999). FEBS Lett., 460, 246-250.
16. Carpentier I, Declercq W, Malinin NL, Wallach D, Fiers W and Beyaert R. (1998). FEBS Lett., 425, 195-198.
17. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME and Dixit VM. (1996). J. Biol. Chem., 271, 4961-4965.
18. Cosset FL, Takeuchi Y, Battini JL, Weiss RA and Collins MK. (1995). J. Virol., 69, 7430-7436.
19. Daniel PT and Krammer PH. (1994). J. Immunol., 152, 5624-5632.
20. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R and Dörken B. (1997). Eur. J. Immunol., 27, 1029-1034.
21. Daniel PT, Schulze-Osthoff K, Belka C and Güner D. (2003). Essays Biochem., 39, 73-88.
22. Daniel PT, Sturm I, Wieder T and Schulze-Osthoff K. (2001). Leukemia, 15, 1022-1032.
23. de Almodovar CR, Ruiz-Ruiz C, Munoz-Pinedo C, Robledo G and Lopez-Rivas A. (2001). Oncogene, 20, 7128-7133.
24. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou J. (1999). J. Cell. Biol., 144, 891-901.
25. De Valck D, Jin DY, Heyninck K, Van de Craen M, Contreras R, Fiers W, Jeang KT and Beyaert R. (1999). Oncogene, 18, 4182-4190.
26. Dhein J, Behrmann I, Daniel PT, Debatin KM, Klas C, Moller P, Oehm A, Trauth BC, Walczak H and Krammer PH. (1994). Biochem. Soc. Trans., 22, 598-600.
27. Droin N, Bichat F, Rebe C, Wotawa A, Sordet O, Hammann A, Bertrand R and Solary E. (2001). Blood, 97, 1835-1844.
28. El-Deiry WS. (2001). Cell Death Differ., 8, 1066-1075.
29. Eskes R, Desagher S, Antonsson B and Martinou JC. (2000). Mol. Cell. Biol., 20, 929-935.
30. Essmann F, Wieder T, Otto A, Muller EC, Dörken B and Daniel PT. (2000). Biochem. J., 346, 777-783.
31. Fiers W, Beyaert R, Boone E, Cornelis S, Declercq W, Decoster E, Denecker G, Depuydt B, De Valck D, De Wilde G, Goossens V, Grooten J, Haegeman G, Heyninck K, Penning L, Plaisance S, Vancompernolle K, Van Criekinge W, Vandenabeele P, Vanden Berghe W, Van de Craen M, Vandevoorde V and Vercammen D. (1995). J. Inflamm., 47, 67-75.
32. Fortis C, Biswas P, Soldini L, Veglia F, Careddu AM, Delfanti F, Mantelli B, Murone M, Lazzarin A and Poli G. (1999). Eur. J. Immunol., 29, 2662-3654.
33. Friedrich K, Wieder T, von Haefen C, Radetzki S, Schulze-Osthoff K, Jänicke R, Dörken B and Daniel PT. (2001). Oncogene, 20, 2460-2749.
34. Fulda S, Meyer E and Debatin KM. (2002). Oncogene, 21, 2283-2294.
35. Geilen CC, Bektas M, Wieder T and Orfanos CE. (1996). FEBS Lett., 378, 88-92.
36. Goossens V, Grooten J, De Vos K and Fiers W. (1995). Proc. Natl. Acad. Sci. USA, 92, 8115-8119.
37. Gottlieb E, Vander Heiden MG and Thompson CB. (2000). Mol. Cell. Biol., 20, 5680-5689.
38. Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K and Slater JM. (1997). Oncol. Res., 9, 217-227.
39. Guiet C, Silvestri E, De Smaele E, Franzoso G and Vito P. (2002). Cell Death Differ., 9, 138-144.
40. Hannun YA. (1996). Science, 274, 1855-1859.
41. Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B and Daniel PT. (2004). Oncogene, 23, 4523-4535.
42. Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B and Daniel PT. (2002). Oncogene, 21, 3149-3161.
43. He Q, Huang Y, Sheikh MS, Troy CM and Shelanski ML. (2004). Oncogene, 23, 1321-1325.
44. Heyninck K and Beyaert R. (2001). Mol. Cell. Biol. Res. Commun., 4, 259-265.
45. Jänicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K and Porter AG. (2001). Oncogene, 20, 5043-5053.
46. Khwaja A and Taton L. (1999). J. Biol. Chem., 51, 36817-36823.
47. Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ and Lee MS. (2002). Oncogene, 21, 3139-3148.
48. Kimura K, Bowen C, Spiegel S and Gelmann EP. (1999). Cancer Res., 59, 1606-1614.
49. Kolesnick RN, Haimovitz-Friedman A and Fuks Z. (1994). Biochem. Cell. Biol., 72, 471-474.
50. Kontny HU, Hammerle K, Klein R, Shayan P, Mackall CL and Niemeyer CM. (2001). Cell Death Differ., 8, 506-514.
51. Krönke M. (1999). Chem. Phys. Lipids, 102, 157-166.
52. Lassus P, Opitz-Araya X and Lazebnik Y. (2002). Science, 297, 1352-1354.
53. Li H, Zhu H, Xu C and Yuan J. (1998). Cell, 94, 491-501.
54. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X. (1997). Cell, 91, 479-489.
55. Los M, Wesselborg S and Schulze-Osthoff K. (1999). Immunity, 10, 629-639.
56. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X. (1998). Cell, 94, 481-490.
57. Luschen S, Ussat S, Scherer G, Kabelitz D and Adam-Klages S. (2000). J. Biol. Chem., 275, 24670-24678.
58. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH and Cohen GM. (2002). Oncogene, 21, 6809-6818.
59. Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ and Young LS. (2002). Cell Death Differ., 9, 287-300.
60. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM. (1996). Cell, 85, 817-827.
61. Muzio M, Salvesen GS and Dixit VM. (1997). J. Biol. Chem., 272, 2952-2956.
62. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, Kuida K, Strasser A, Huang DC and Kumar S. (2002). Cell Death Differ., 9, 832-841.
63. Paroni G, Henderson C, Schneider C and Brancolini C. (2001). J. Biol. Chem., 276, 21907-21915.
64. Perez D and White E. (2000). Mol. Cell, 6, 53-63.
65. Peter ME. (2000). Cell Death Differ., 7, 759-760.
66. Prajapati S and Gaynor RB. (2002). J. Biol. Chem., 277, 24331-24339.
67. Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT. (2002). Oncogene, 21, 227-238.
68. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z and Rothe M. (1997). Cell, 90, 373-383.
69. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B and Orrenius S. (2002). J. Biol. Chem., 277, 29803-29809.
70. Roy N, Deveraux QL, Takashashi R, Salvesen GS and Reed JC. (1997). EMBO J., 16, 6914-6925.
71. Ruffolo SC, Breckenridge DG, Nguyen M, Goping IS, Gross A, Korsmeyer SJ, Li H, Yuan J and Shore GC. (2000). Cell Death Differ., 7, 1101-1108.
72. Salvesen GS and Dixit VM. (1999). Proc. Natl. Acad. Sci. USA, 96, 10964-10967.
73. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA and Fiers W. (1992). J. Biol. Chem., 267, 5317-5323.
74. Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G and Fiers W. (1993). EMBO J., 12, 3095-3104.
75. Schwandtner R, Wiegmann K, Bernardo K, Kreder D and Krönke M. (1998). J. Biol. Chem., 273, 5916-5922.
76. Shatrov VA, Ameyar M, Bouquet C, Cai Z, Stancou R, Haddada H and Chouaib S. (2000). Int. J. Cancer, 85, 93-97.
77. Shearwin-Whyatt LM, Harvey NL and Kumar S. (2000). Cell Death Differ., 7, 155-165.
78. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ. (1999). J. Cell. Biol., 144, 281-292.
79. Smirnov AS, Ruzov AS, Budanov AV, Prokhortchouk AV, Ivanov AV and Prokhortchouk EB. (2001). Cell Death Differ., 8, 621-630.
80. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA and Walczak H. (2002). EMBO J., 21, 4520-4530.
81. Suffys P, Beyaert R, Van Roy F and Fiers W. (1989). Anticancer Res., 9, 167-171.
82. Troy CM and Shelanski ML. (2003). Cell Death Differ., 10, 101-107.
83. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM. (1996). Science, 274, 787-789.
84. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT. (2003). Oncogene, 22, 2236-2247.
85. von Haefen C, Wieder T, Gillissen B, Starck L, Graupner V, Dörken B and Daniel PT. (2002). Oncogene, 21, 4009-4019.
86. Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, Goncharov TM, Kovalenko AV, Rajput A, Varfolomeev EE and Zhang S. (2002). Arthritis Res., 4 (Suppl 3), S189-S196.
87. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP. (1999). Annu. Rev. Immunol., 17, 331-367.
88. Wang C, Mayo M, Korneluk R, Goeddel D and Baldwin A. (1998). Science, 281, 1680-1683.
89. Wesselborg S, Engels IH, Rossmann E, Los M and Schulze-Osthoff K. (1999). Blood, 93, 3053-3063.
90. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B and Daniel PT. (2001a). Blood, 97, 1378-1387.
91. Wieder T, Orfanos CE and Geilen CC. (1998). J. Biol. Chem., 273, 11025-11031.
92. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz HG, Daniel PT and Henze G. (2001b). Leukemia, 15, 1735-1742.
93. Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J and Escandon E. (2002). Oncogene, 21, 3611-3619.
94. Yaron A, Hatzubai A, Davis M, Lavori I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah Y. (1998). Nature, 396, 590-594.